Last reviewed · How we verify

Losartan + Simvastatin — Competitive Intelligence Brief

Losartan + Simvastatin (Losartan + Simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist + HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed Angiotensin II receptor antagonist + HMG-CoA reductase inhibitor (statin) Angiotensin II type 1 receptor (AT1R) + HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Losartan + Simvastatin (Losartan + Simvastatin) — University of Pavia. This combination reduces blood pressure via angiotensin II receptor blockade and lowers cholesterol via HMG-CoA reductase inhibition, addressing both hypertension and dyslipidemia simultaneously.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Losartan + Simvastatin TARGET Losartan + Simvastatin University of Pavia marketed Angiotensin II receptor antagonist + HMG-CoA reductase inhibitor (statin) Angiotensin II type 1 receptor (AT1R) + HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist + HMG-CoA reductase inhibitor (statin) class)

  1. University of Pavia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Losartan + Simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-simvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: